Q3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Analyst

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Barrington Research dropped their Q3 2025 EPS estimates for shares of Surmodics in a report issued on Thursday, May 2nd. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $0.09 per share for the quarter, down from their previous estimate of $0.10. Barrington Research has a “Outperform” rating and a $71.00 price objective on the stock. The consensus estimate for Surmodics’ current full-year earnings is ($0.57) per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.15 EPS and FY2026 earnings at $0.88 EPS.

Several other research firms have also weighed in on SRDX. Needham & Company LLC lowered their price objective on shares of Surmodics from $47.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. StockNews.com lowered shares of Surmodics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 24th.

Surmodics Stock Down 6.0 %

Surmodics stock opened at $32.49 on Monday. The firm has a market capitalization of $463.31 million, a PE ratio of 34.20 and a beta of 1.04. The company’s 50-day moving average is $28.63 and its 200-day moving average is $31.67. Surmodics has a fifty-two week low of $16.79 and a fifty-two week high of $39.41. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.39 and a quick ratio of 3.97.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.43. The company had revenue of $31.96 million for the quarter, compared to analyst estimates of $28.79 million. Surmodics had a net margin of 9.44% and a return on equity of 13.30%. During the same period in the previous year, the business earned ($0.40) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SRDX. SG Americas Securities LLC bought a new stake in Surmodics in the 4th quarter valued at about $163,000. Hillsdale Investment Management Inc. boosted its holdings in Surmodics by 15.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after purchasing an additional 620 shares during the period. BNP Paribas Financial Markets boosted its holdings in Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after purchasing an additional 481 shares during the period. Mesirow Financial Investment Management Inc. bought a new stake in Surmodics in the 1st quarter valued at about $223,000. Finally, Strs Ohio lifted its holdings in shares of Surmodics by 97.2% during the 4th quarter. Strs Ohio now owns 7,100 shares of the company’s stock worth $258,000 after acquiring an additional 3,500 shares during the period. Institutional investors and hedge funds own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).